Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Cancer

Date Submitted: Nov 20, 2018
Open Peer Review Period: Dec 3, 2018 - Jan 28, 2019
Date Accepted: Mar 29, 2019
(closed for review but you can still tweet)

The final, peer-reviewed published version of this preprint can be found here:

When Chatbots Meet Patients: One-Year Prospective Study of Conversations Between Patients With Breast Cancer and a Chatbot

Chaix B, Bibault JE, Pienkowski A, Delamon G, Guillemassé A, Nectoux P, Brouard B

When Chatbots Meet Patients: One-Year Prospective Study of Conversations Between Patients With Breast Cancer and a Chatbot

JMIR Cancer 2019;5(1):e12856

DOI: 10.2196/12856

PMID: 31045505

PMCID: 6521209

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

When Chatbots Meet Patients: One-Year Prospective Study of Conversations Between Patients With Breast Cancer and a Chatbot

  • Benjamin Chaix; 
  • Jean-Emmanuel Bibault; 
  • Arthur Pienkowski; 
  • Guillaume Delamon; 
  • Arthur Guillemassé; 
  • Pierre Nectoux; 
  • Benoît Brouard

Background:

A chatbot is a software that interacts with users by simulating a human conversation through text or voice via smartphones or computers. It could be a solution to follow up with patients during their disease while saving time for health care providers.

Objective:

The aim of this study was to evaluate one year of conversations between patients with breast cancer and a chatbot.

Methods:

Wefight Inc designed a chatbot (Vik) to empower patients with breast cancer and their relatives. Vik responds to the fears and concerns of patients with breast cancer using personalized insights through text messages. We conducted a prospective study by analyzing the users’ and patients’ data, their usage duration, their interest in the various educational contents proposed, and their level of interactivity. Patients were women with breast cancer or under remission.

Results:

A total of 4737 patients were included. Results showed that an average of 132,970 messages exchanged per month was observed between patients and the chatbot, Vik. Thus, we calculated the average medication adherence rate over 4 weeks by using a prescription reminder function, and we showed that the more the patients used the chatbot, the more adherent they were. Patients regularly left positive comments and recommended Vik to their friends. The overall satisfaction was 93.95% (900/958). When asked what Vik meant to them and what Vik brought them, 88.00% (943/958) said that Vik provided them with support and helped them track their treatment effectively.

Conclusions:

We demonstrated that it is possible to obtain support through a chatbot since Vik improved the medication adherence rate of patients with breast cancer.


 Citation

Please cite as:

Chaix B, Bibault JE, Pienkowski A, Delamon G, Guillemassé A, Nectoux P, Brouard B

When Chatbots Meet Patients: One-Year Prospective Study of Conversations Between Patients With Breast Cancer and a Chatbot

JMIR Cancer 2019;5(1):e12856

DOI: 10.2196/12856

PMID: 31045505

PMCID: 6521209

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.